ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

<p><strong>Background</strong> This randomized phase 2 trial compared the efficacy and safety of second‐line nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) with or without the addition of CC‐486 (an oral formulation of 5‐azacytidine) in patients with advanced‐stage, nonsqua...

תיאור מלא

מידע ביבליוגרפי
Main Authors: Morgensztern, D, Cobo, M, Ponce Aix, S, Postmus, PE, Lewanski, CR, Bennouna, J, Fischer, JR, Juan-Vidal, O, Stewart, DJ, Fasola, G, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Talbot, DC, Jin Ong, T, Govindan, R, On Behalf Of The Abound L Investigators
פורמט: Journal article
שפה:English
יצא לאור: Wiley 2018

פריטים דומים